全球乳腺癌發(fā)病率呈逐年上升趨勢(shì),已經(jīng)成為當(dāng)前社會(huì)的重大公共衛(wèi)生問(wèn)題。細(xì)胞周期蛋白依賴性激酶(CDK)4/6抑制劑將細(xì)胞周期阻滯于G₁期,從而起到抑制腫瘤增殖的作用。ribociclib屬于高度特異性CDK4/6雙重抑制劑,可靶向抑制D1/CDK4、D3/CDK6細(xì)胞周期,具有潛在的抗腫瘤活性。臨床試驗(yàn)結(jié)果表明ribociclib可用于乳腺癌、黑色素瘤、非小細(xì)胞肺癌、畸胎瘤、脂肪肉瘤和膠質(zhì)母細(xì)胞瘤的治療。

The incidence of breast cancer is increasing year by year, and has become a major public health problem in the world. Cycle dependent protein kinase (CDK) 4/6 inhibitor can block cell cycle in G₁ phase, which can inhibit tumor growth. Ribociclib is a highly specific protein kinases 4/6 inhibitor, which can inhibit D1/CDK4 and D3/CDK6 cell cycle, and has potential antitumor activity. The results of clinical trials indicate that ribociclib has clinical efficacy in treatment of breast cancer, melanoma, non-small cell lung cancer, teratoma, liposarcoma, and glioblastoma.